Life Sciences Archive » October, 2021

Life Sciences - October, 2021

335 articles

• FDA Authorizes Pfizer Vaccine For Children Aged 5 To 11
• 10 States Sue Biden Over Federal Contractor Vax Mandate
• 5 Details To Know Before High Court Mulls Texas Abortion Ban
• Ill. Judge Won't Halt COVID-19 Vaccine And Testing Mandates
• US Backs Patients In High Court CVS Disability Bias Case
• Mallinckrodt Votes Disputed On Eve Of Ch. 11 Plan Hearing
• FTC Republicans Blast 'Zombie Vote' On Merger Policy
• Endo, Arnold & Porter Split Amid Opioid Litigation Troubles
• Fed. Circ. Axes Philips Heart Monitor Patent Under Alice
• Orangetheory Branch Hit With Suit Alleging Spam Texts
• Fed. Circ. Backs PTAB Decision Upholding HandyLab Patents
• Takeda Takes Home Some Injunctions In Generic Drug Battle
• Quinn Emanuel Can't Escape Insys Ch. 11 Suit Over Payments
• EU Imposes Safeguards For Illumina-Grail Deal During Review
• Shkreli Can't Take The Stand Remotely At FTC Antitrust Trial
• 'Bully' Priest Engineered Biotech Stock Drop, Jury Told
• Canadian Mining Co. Lied To Drive Up Stock Price, Class Says
• Mylan Loses Bid To Stall Trial Over Neurim's Melatonin Patent
• Fed. Circ. Forecast: USPTO To Face Inventor's Bias Claims
• Investor Sues Gas Co. Over Merger Details With Sinclair Oil
• Ex-Aegerion Rep Not 'Over The Law,' Gets 4 Years For Fraud
• Walgreens, CVS Eye Prescription Data In Tribe's Opioid Row
• Illumina Insider Trading Merits 10-Year Sentence, Feds Say
• Flanax Trademark Case Exposes Circuit Rifts, High Court Told
• Juno Urges Fed. Circ. To Undo 'Mischief' In Wiping $1B IP Win
• Avoro Capital Slams Merck's $11.5B Acceleron Deal
• J&J Unit Escapes Antitrust Suit Over Prostate Cancer Drug
• Freshfields Snags 2 Arnold & Porter Life Sciences Partners
• The Most Active Firms In Public False Claims Cases
• Philip Morris Can't Block Cig Warning Rule Set For Late 2022
• Academics Back Illumina's Grail Buy Against FTC Challenge
• Regeneron Gets PTAB To Review Syringe Patent On 2nd Go
• CBD Retailer, Manufacturer Slip Claims They Stole Cream IP
• 2nd Circ. Voices Support For NY Health Care Worker Vax Rule
• Avadim's Ch. 11 Plan Confirmed Over Release Objections
• 'The Genome Defense' Brings Myriad Battle To Life
• Lawyers Can And Should Commit To Climate Action
• FCA Ruling Guides Insureds On Classifying Restitution Costs
• Giant Eagle Strikes Deal To Leave Ohio Opioid Bellwether
• Allergan, Others Appeal £260M Antitrust Fine Over Drug Prices
• Pharmacy Exec Asks Full 1st Circ. To Toss Meningitis Case
• Copyright Office Floats Expanding Right To Repair Devices
• DeVos Family Gave Theranos $100M 'On The Spot,' Jury Told
• Pharmacy Owner Must Disclose Atty Advice In $1B Fraud Trial
• DOJ Accuses Kaiser Of $1B Medicare Fraud, Fake Diagnoses
• Pharma Co. Beats NJ Whistleblower Suit Over Contract Claim
• Skadden Strives To Tame Flames In Endo's Opioid Imbroglio
• Chicago Workers Ask Ill. Judge To Block COVID Vax Mandates
• Insurer, Surgical Supplier Settle Coverage Fight Over J&J Suit
• Imerys Seeks Ch. 11 Mediator After Plan Process Stalls
• ViSalus Seeks 9th Circ. Reprieve From $925M TCPA Verdict
• 5th Circ. Allows Texas Co.'s E-Cigs To Stay On Market
• FDA Panel Backs Pfizer COVID Vaccine In Kids Aged 5-11
• EpiPen Buyers Can't Appeal Order Yet In Antitrust Case
• Feds Want 6 Years For Aegerion Rep's 'Sophisticated' Fraud
• Church & Dwight Escapes Zicam Cold Remedy False Ad Suit
• WTO Nominee Sees Vaccine IP Waiver Talks As 'Sort Of Stuck'
• Leafly Wins Challenge To Fla.'s Medical Pot Online Order Rule
• Insys Execs Owe $48M For Duping Insurers 'All Day,' Feds Say
• Husch Blackwell Scoops Up Lewis Brisbois Labor Leader
• Clinical Research Biz Medable Lands $2B Valuation In Series D
• Opioid Expert's Addiction Calculations Off Base, Jury Hears
• Biden Admin. Announces Vaccine Rules For Int'l Travelers
• J&J Unit Hit With Motion To Send Ch. 11 To New Jersey
• Nevro Loses 11th-Hour Bid To Delay Boston Scientific IP Trial
• Texas Judge Won't Block State's Delta-8 THC Ban, For Now
• Parties In Zantac MDL Propose Path To 2023 Bellwether Trials
• NYPD Union Sues Over 'Draconian' COVID Vaccine Mandate
• Pharmacies' Mistrial Bid Shot Down In Opioid Bellwether
• FTC Formally Reinstitutes 'Prior Approval' In Merger Deals
• St. Jude Medical Wins Atty Fees In Catheter Method IP Suit
• Insurance Coverage Vet Joins Miller Nash Cannabis Team
• Parsing Boeing Decision In Light Of ESG, Caremark Trends
• Confronting Origination Credit: Why GCs Need To Speak Up
• What Evolution Of Public Nuisance Claims Means For Cos.
• CVS Says Ex-Worker Openly Broke Nonsolicitation Agreement
• Purdue Opposes Requests To Delay Ch. 11 Plan For Appeals
• NJ High Court Takes On Nix Of $83M J&J, Bard Mesh Verdicts
• EU Raids Animal Pharma Co. In Probe Of Possible Cartel
• J&J Talc Suits Can Proceed For Now Despite Ch. 11 Filing
• High Court At High Speed: Abortion Cases' Pace Stirs Interest
• Ex-Pfizer Scientist Rips Report Holmes Sent To Walgreens
• Ranbaxy Argues It Can't Monopolize Drugs It Never Sold
• 2nd Circ. Says No To Third Shot At Vitamin C Exporters
• Virginia Judge Ships Suit Over AbbVie's Humira To Illinois
• Pharma Co. Wants €140M AOP Orphan Award Suit Tossed
• 4 Firms Rep $193M In Biotech, Life Sciences-Focused IPOs
• What Blockchain Means For The Future Of US Health Care
• Chicago Workers Sue Governor, City Over Vaccine Mandates
• Ex-Insys CEO Gets 8 Months Shaved Off Prison Term
• White & Case Program Aims To Draw Students To IP Law
• Insurer Says Exclusions Apply To Pharma Co.'s BIPA Suit
• 3 Firms Rep 23andMe's $400M Buy Of Telehealth Biz Lemonaid
• Beltway Moves: Ex-Trump DOJ Official, Covington, O'Melveny
• Burns & Levinson Snags Patent Ace From Dinsmore & Shohl
• Texas Firm Wants Pharma Co. To Pay $113K Arbitration Award
• Justices Will Hear Challenges To Texas' 6-Week Abortion Law
• Goodwin Adds Life Sciences Partner From Hogan Lovells
• UK Litigation Roundup: Here's What You Missed In London
• CDC Backs COVID-19 Booster Shots For All 3 Vaccines
• IP Forecast: Google Lyrics Battle To Play Out At 2nd Circ.
• 5 Accused Of Laundering Funds From Venezuela Bribery Plot
• Del. Justices Uphold $275M AstraZeneca Drug Trial Debt Toss
• Fla. Official Blasts New Pot License Rules As Discriminatory
• Hill-Rom, Baxter Get FTC Warning Letters For $12.4B Deal
• Texas Rips DOJ's 'Extraordinary' Abortion Suit At High Court
• Apotex Backs Teva's En Banc Bid In Skinny Label Fight
• What To Watch In Telehealth Enforcement
• Ex-Ventilator Exec Must Face Poaching Suit, 1st Circ. Told
• Venue Change On Table For J&J Talc Unit's Ch. 11
• Feds Oppose Service Members' Anonymity In Vaccine Suit
• McKesson Nears Win On Some Securities Fraud Claims
• Atty Accused Of 'Heinous Fraud' With Privileged Insys Docs
• Woman Keeps $1.2M Med Mal Verdict Over Spinal Surgery
• 'Mix-And-Match' COVID-19 Boosters Win FDA Clearance
• Holmes Was Coached By Marketing Firms, Jury Told
• Bayer Will Have To Face Investor Suit Over Roundup Litigation
• Eli Lilly Must Pay Royalties In Diabetes Drug Row, Judge Says
• J&J, Ethicon Beat Pa. Woman's Untimely Hernia Mesh Suit
• Mylan Asks Fed. Circ. To Flip PTAB's Ruling On Merck Patent
• Rutgers Aims To Unmask Students Behind COVID Vaccine Suit
• Chancery Won't Delay CytoDyn Board Meeting
• 8th Circ. Sends Civilians' 3M Earplug Suits To State Court
• Atrium Wins Quick Verdict In Chicago In 1st Hernia Mesh Trial
• Purdue Asks To Pay Ch. 11 Costs Of Government Committees
• 3 Firms Shape $430M Carlyle-Led Pharma Analytics Co. Boost
• Judge Will Rethink SEC's Partial Win Against Ex-Biotech CEO
• 1st Circ. Clears Vax Mandate For Maine Health Care Workers
• How To Overcome Risks Of Virtual Expert Testimony
• Financial Planning Tips For Retiring Law Firm Partners
• 4 Practical Pointers For Litigating A Design Patent Case
• Teva Fears 'Incredibly Damaging' Parody Videos In Opioid Trial
• Holmes OK'd Testing Claims Over Atty's Concerns, Jury Told
• Shkreli Cites Rehab Too Late To Delay FTC Antitrust Trial
• Christian Employers Target Trans Health Coverage Rules
• AGs Want Facebook's Logs On Vax 'Disinfo Dozen'
• Taiwanese Pharma Co. Fights AOP Orphan's Sanctions Bid
• Teva Fights Eli Lilly's Bid To Toss Migraine Drug IP Case
• Preparing Remote Deposition Defenses For Corporate Entities
• Cleary-Led Chipmaker Leads Four IPO Launches Totaling $4B
• Rutgers Students Want To Hide Names In COVID Vaccine Suit
• How Food Safety Ruling Supports FDA Framework
• Del. Judge Puts Off Ruling On HHS Discount Pharmacy Fight
• Md. Judge Refuses Sanctions In Superfund Cleanup Case
• J&J's Bankrupt Unit Says Ch. 11 Stay Extends To Parent Co.
• Generic-Drug Group Wants Justices To Intervene Against FTC
• Tech, Life Sciences Spar Over Eligibility In USPTO Comments
• Texas Has 'Nullified' Abortion Right, DOJ Tells Justices
• FDA Clears 1st Drug Interchangeable With AbbVie's Humira
• FTC Says Shkreli Has No Good Reason To Delay Antitrust Trial
• Walmart Blasts Ohio Counties' Sanctions Bid In Opioid Trial
• Fed. Circ. Won't Eye Decision Upholding Teva Cancer Drug IP
• Rejected CytoDyn Slate Seeks Injunction After Del. Ruling
• Strategies To Counter Broad Approach To IPR Estoppel
• Amarin Investors Want 3rd Circ. To Revive Heart Drug Suit
• Why Law Schools Should Require Justice Reform Curriculum
• Opioid Inquiry Faults Arnold & Porter But Rejects Some Relief
• Endo Investors Ink $63M Deal In Generics Stock Inflation Suit
• Teligent's Distributors Balk At Customer Risks In Ch. 11
• Most Cancer Claims Survive In Suit Over Weight Loss Drug
• Theranos' Test Demo Hid Failures From Investors, Jury Told
• Zydus Infringed AstraZeneca's Diabetes Drug IP, Judge Rules
• Skin Care Co. Ordered To Pay $2.3M For Copied Packaging
• NY Counties Sound Alarm Over Doctor As Opioid Trial Witness
• Brand Battles: DC Comics Faces TM Fight Over 'The Flash'
• Polo Star Wants Court To Block Sales Of Cloned Horse
• UK Litigation Roundup: Here's What You Missed In London
• Compliance Tips For Marketing Health Benefits In Alcohol
• Resistance To J&J's Bankruptcy Gambit May Be Futile
• DOJ Unveils 3 Settlements, $20M Neuro-Stimulator Fraud Suit
• Nimbus, Bristol-Myers Can't Sell Psoriasis Drug Amid Dispute
• Latham-Led Orthopedics Firm Leads 2 IPOs Totaling $165M
• UK Watchdog Probing Thermo Fisher's $21B PPD Deal
• Nelson Mullins Adds 2 Morris Manning Health Care Attys
• Health Hires: Orrick, Sheppard Mullin
• Goodwin Snags Another Litigator From Manatt In SoCal
• Convicted Insys Founder Seeks Deep Cut To Restitution
• Mallinckrodt Ch.11 Plan Under Fire From Multiple Angles
• FDA Panel Backs J&J COVID Booster For Ages 18 And Up
• DuPont, Others Must Face NJ Water Co.'s Pollution Suit
• Boehringer Loses Bad Faith Claim In Diabetes Drug Deal Suit
• Pharmacies Slam Cherokee Bid To Remand Opioid Claims
• CR Bard Can't Escape Texas Man's Heart Filter Suit
• 5th Circ. Says Texas Abortion Law Can Be Enforced For Now
• Holmes Prayed As WSJ Reporter Raised Doubts, Jury Told
• Shkreli Wants FTC's Monopolization Trial Pushed Back
• Insurer Says Lab Charged Up To $979 Per COVID-19 Test
• Dental Co. To Pay $63M To End Investors' Price-Fixing Suit
• Lawmakers Say Moderna Deal May Let Gov't Share Vax Recipe
• Texas Judge Wants Unions' Input On United Vaccine Mandate
• Fenwick-Led Software Company Among 3 IPOs Raising $1.2B
• Johnson & Johnson Puts Talc Spinoff Into Ch. 11
• College Of NJ Students Can't Halt COVID-19 Vaccine Mandate
• 9th Circ. Chromium Ruling May Expand Water System Liability
• WTO Makes Some Progress On COVID IP Waiver Talks
• Purdue Ch. 11 Plan Challenges Won't Hit 2nd Circ. Right Away
• McDermott Continues Energy Hiring With Baker McKenzie Atty
• Chancery Rejects CytoDyn Dissidents' Late Board Slate Bid
• Barnes & Thornburg Snags IP Partner From Womble Bond
• NYC Teacher Vax Rule Seems Likely To Pass 2nd Circ. Test
• Pharma Co. Teligent Opens Ch. 11 In Del. With $130M Debt
• Ex-Walgreens Exec Told Holmes 'Haters Are Everywhere'
• Texas Judge Doubts He Can Stop United's Vaccine Mandate
• Counsel In $1.8B Biotech Sale Suit Urged To Work Together
• Teamsters Can't Arbitrate Mandatory COVID-19 Vaccine Policy
• Investor Says Biotech Co. Hid Issues Leading To Delays
• Louisiana Can't Wade Into FTC's Settled Provigil Case
• Bayer Tells High Court To Curb Flanax Fight Again
• Judge Tosses 16K Talc Claimant Votes In Imerys Ch. 11
• Del. Justices Probe Unclear Terms In AstraZeneca Merger Pact
• Pain Doc Tells NY Jury Consulting Work Didn't Hurt Patients
• EPA Takes First Step Toward Ethylene Oxide Reporting
• Quinn Emanuel Loses Latest Partner To White & Case
• Rhode Island Balks At Mallinckrodt Ch. 11's CEO Release
• California Sued Over Vaccination Site 'Bubble Zone' Law
• ​​​​​​​Philips Hit With $200M Suit By CPAP Cleaner Co. Over Recall
• Girardi Scandal Provides Important Ethics Lessons
• How Social Media, Mass Torts Affect Adverse Event Reports
• Allergan Inks $30M Deal With Restasis Buyers In Antitrust Suit
• NORML Warns Against Unregulated Delta-8 Products
• Quarles & Brady Nabs Veteran SDNY Assistant Atty
• Pfizer Gives Gov't More Time To Study $2.3B Trillium Deal
• Latham Helped Vet Theranos Deal, Ex-Safeway CEO Says
• Fed. Circ. Told Minerva Still Can't Challenge Hologic Patent
• Sanofi Whistleblowers Were Legitimately Fired, NJ Court Told
• Janssen Wins Push To Arbitrate Zytiga Generic Delay Suit
• 2 Firms Guide PharmaCann's Colo. Pot Co. Acquisition
• FDA Approves 3 RJ Reynolds Vaping Products
• Embracing ESG: Jabil GC Talks Compliance Preparation
• Home Health Cos. Ink $8.5M Deal In Medicare Row, Feds Say
• Insurer Accuses Jazz Pharma Of 'Grotesque' Antitrust Scheme
• Predicting Fed. Circ. Rule 36 Affirmances In Patent Cases
• NYC Vaccine Orders Survive Scrutiny In 2 Court Rulings
• Purdue Ch. 11 Appeals To Be Heard Before Plan Effective Date
• Philips Sleep Apnea Device Suits Sent To Pa. Federal Court
• Foley & Lardner Opens Salt Lake City Office With IP Team
• Hot Dog Restaurateur Leads 5 IPO Launches Exceeding $1B
• Chubb Unit Must Cover $10M Of Drugmaker's DOJ Settlement
• Bankruptcy Venue Reform Bill Needs Amending
• Top Court Won't Review Toss Of $1M Abbott Age Bias Award
• Pfizer Sold Carcinogen-Tainted Chantix, Buyers Claim
• Pot Biz Residency Rules To Face Biggest Challenge Yet
• McKesson Wins Class Decertification In 'Junk Fax' Fight
• NY Judge Doubts Challenge To Vax Mandate But Grills City
• FTC's Chopra Knocks Agency's Merger Remedies Study
• GOP Sen. Says Waiving COVID Copyrights Also 'Devastating'
• Health Hires: Manatt, Holland & Knight
• 9th Circ. Affirms Siemens Win In False Ads Appeal
• JPML Sends J&J Sunscreen Carcinogen Suits To Florida
• 3 Ways CLOs Can Drive ESG Efforts
• China Tariff Relief Is Back, And So Is Importers' Angst
• Why Congress Should Pass Whistleblower Protection Law
• New Trial Sought In CR Bard Hernia Mesh Bellwether
• 2 Cases Will Help Shape Opioid Litigation Insurance Coverage
• Green Groups Blast Exxon's 'Tortured' Appeal Of $14M Award
• NJ Medical Device Co. Must Face Class Claims Over IPO
• Canadian Creditors Seek Direct Appeal Of Purdue Ch. 11 Plan
• FDA 'Vaccine' Label Not Last Word On Mandate, Court Told
• UK Litigation Roundup: Here's What You Missed In London
• Taxation With Representation: Shearman, Latham, Boggs
• Teva Gets Bayer's Cancer Drug Patent Invalidated In UK
• Hearing Aid Co. Sued Over DOJ Insurance Claims Probe
• IP Forecast: SAP To Spar Over Trade Secrets, Patents
• Moderna Faces Skeptical Fed. Circ. On Threat To COVID Shot
• United Moves To Trim COVID-19 Vax Mandate Suit
• How Law Firms Can Rethink Offices In A Post-Pandemic World
• College's Unvaccinated Athletes Can Play, 6th Circ. Says
• Teva Says GSK Skinny Label Win Will Have 'Seismic' Impact
• HHS Accused Of Overstepping Role In Drug Discount Program
• Doc Can Subpoena Yelp User Info In Botox Defamation Suit
• NJ Panel Revives Aetna's Fraud Claims Over Lab's Crimes
• MabVax Brass Slip Suit By Alleged Pump-And-Dump Investor
• Drug Cos. Can't Nix Monitoring Class In Zantac MDL
• Ex-Safeway CEO Says Theranos Didn't Deliver On $55M Deal
• Walgreens, Purdue 'Colluded' To Spread Opioids, Jury Hears
• Court Sides With Rival In AbbVie's Trade Secrets Suit
• Mallinckrodt Facing $93M Drug Royalty Claim In Ch. 11
• Synthego Says It Doesn't Infringe Agilent CRISPR Patents
• A Cell For A Stall: Jailed Exec Wants Out To Run Horse Farm
• Inyx Fraudster Seeks New Trial Over Jury Instructions 'Error'
• SC AG Says Congress Likely Didn't Legalize Delta-8 THC
• PTAB Revision Bill Offers US Makers Much-Needed Protection
• DOL Urges Revival Of Hartford ERISA Suit At 2nd Circ.
• Protecting Attorney-Client Privilege In Human Rights Audits
• Boston Scientific Boosts Heart Biz With $1.75B Baylis Buy
• Ex-Theranos Lab Chief Says Ebola Rumor Was 'Final Straw'
• CVS, Walmart Opioid Trial Defense Hazy On Pharmacists' Role
• King & Spalding Nabs Dechert International Arbitration Atty
• Fed. Circ. Upends St. Jude's PTAB Win In Heart Valve IP Row
• NY's New Pot Regulators Expand Access To Medical Patients
• AOP Orphan Seeks Sanctions On Taiwanese Pharma Co.
• Wash. Tribal Corp. Says Stanford Used Its IP For Drug Patent
• Perrigo To Pay $31.9M To Settle Tax Suit With Fla. Groups
• USTR May Revive Tariff Breaks On Over 500 Chinese Goods
• Senate Bill Targets Generic Drug Delay Tactic
• Will Kanter Transform Cartel Enforcement?
• Amplify Faces Putative Class Action For 'Catastrophic' Spill
• 3rd Circ. Urged To Nix Future Claims Rep From Imerys Ch. 11
• NJ College Blasts Claim COVID-19 Shots Are Not Vaccines
• Pharmacies' Opioid Screening 'Totally Ineffective,' Jury Hears
• High Court Urged To Take Up Monsanto Roundup Appeal
• Thermo Fisher Sued Over Use Of Henrietta Lacks' Cells
• Justices Duck Jurisdiction Issue On Cases Sent To Fed. Court
• DOL Contractor Watchdog Unveils $3.3M Worth Of Bias Deals
• 9th Circ. Clarifies Timely Removal Of Suits In Boeing Case
• Fed. Circ. Says Art Tool Can't Block Lip Implant Design Patent
• Manufacturers Face Evolving COVID-19 Legal Challenges
• Drugmakers In Zantac MDL Try To Trim Claims
• Justices Turn Away IP Cases Over MS Drug, Costly Prior Art
• J&J Unit Must Face Claims Pelvic Mesh Was Defective
• Illinois Hospital Tries To Escape Antitrust Suit
• Embracing ESG: Baker Hughes CLO Talks Sustainability Team
• Express Scripts Says EpiPen RICO Claims Are Time-Barred
• Commerce Puts Export Curbs On Gene-Editing Software
• Lead Compound Analysis Is Making Inroads At USPTO
• Coding Platform Leads 6 IPO Launches That Could Top $1.8B
• Justices Won't Hear Trade Groups' NY Opioid Tax Challenge
• Counties Say Opioid Trial Can Redress 'Great Stress' Of Crisis
• Sotomayor Rejects NYC Teachers' Bid To Block Vax Mandate
• Ex-Theranos Lab Chief Testifies That Balwani Wasn't Qualified
• Supreme Court's Return Could Deliver Conservative Windfall
• More Than Fintiv: What To Know About The PTAB Revision Bill
• Judge Says Pfizer Heart Drug Copay Program Is A Kickback
• Judge To Reconsider Partial SEC Win Against Ex-Biotech Exec
• Pro Say: A Supreme Court Term Packed With Landmark Cases
• Generic Drug Makers To Pay $447M Over Fixed Prices
• 3 IPOs Across Far-Flung Industries Raise $823M Combined
• Merck Accuses Bayer Of Ducking Product Liability Claims
• Up Next At High Court: State Water Rights, CIA Black Sites
• What Mainstreaming Of Litigation Finance Means For Industry
• Fla. Firm Wins $1M Lien After Client Reneges On Settlement
• Taxation With Representation: Ropes, Kirkland, Latham
• 3rd Circ. Preview: Insurance Drives Ch. 11, Antitrust Cases
• UK Litigation Roundup: Here's What You Missed In London
• Kavanaugh Tests Positive For COVID, Has No Symptoms